Lysine vasopressin in alzheimer disease

R. Durso, P. Fedio, P. Brouwers, C. Cox, A. J. Martin, S. A. Ruggieri, C. A. Tamminga, T. N. Chase

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

The effect of lysine vasopressin on memory and cog nitive deficits in Alzheimer disease was investigated. In a double-blind study, seven patients were given 16 units of lysine vasopressin per day for 10 days and were compared with seven different patients receiving placebo. No significant difference in performance between the vasopressin and placebo-treated groups was found in tests designed to evaluate learning, memory, and perception. However, significantly greater im provement in reaction time was seen in the vasopressin-treated group, although this effect was delayed and may have been contributed to by factors other than drug activity.

Original languageEnglish (US)
Pages (from-to)674-677
Number of pages4
JournalNeurology
Volume32
Issue number6
DOIs
StatePublished - Jun 1982

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Lysine vasopressin in alzheimer disease'. Together they form a unique fingerprint.

  • Cite this

    Durso, R., Fedio, P., Brouwers, P., Cox, C., Martin, A. J., Ruggieri, S. A., Tamminga, C. A., & Chase, T. N. (1982). Lysine vasopressin in alzheimer disease. Neurology, 32(6), 674-677. https://doi.org/10.1212/wnl.32.6.674